Berkeley, CA - Caribou is a clinical-stage biotechnology company, co-founded by CRISPR pioneer and Nobel Prize winner Jennifer Doudna, Ph.D., using next-generation CRISPR genome-editing technology to develop “off-the-shelf” (allogeneic) CAR therapies for hard-to-treat blood cancers.
CB-010, an allogeneic CD19 CAR-T cell therapy in which PD-1 was genetically disrupted in the CAR-T genome, leading to more durable anti-tumor activity in preclinical studies, is being evaluated in a Phase 1 clinical trial expansion cohort for second-line patients with large B cell lymphoma (NCT04637763).
CB-011, an allogeneic BCMA CAR-T cell therapy that is immunologically cloaked for enhanced persistence, is being evaluated in a Phase 1 clinical trial for patients with relapsed or refractory multiple myeloma (NCT05722418).
CB-012, an allogeneic CD371 CAR-T cell therapy, is in preclinical development for the treatment of acute myeloid leukemia with a projected IND filing in the second half of 2023.